At NLS Days 2026, life science companies and a record number of investors attended to showcase data, partner, and raise ...

Explore the preclinical research catching our eye in September 2026, from siRNA and in vivo CRISPR to targeted protein ...

Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his ...

Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline.

Discover how early optimization in stable cell line development accelerates timelines and reduces downstream bottlenecks.

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and ...

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August ...

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science ...

Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs.

At the end of each year, Labiotech selects a list of biotech companies it believes are worth keeping an eye on for the coming year. In December 2023, we highlighted nine biotech companies as “ones to ...